The efficacy of oral treatment with pramiconazole in tinea pedis and tinea cruris/corporis: Two exploratory phase IIa trials

British Journal of Dermatology

Volumn 158, Issue 4, 2008, Pages 854-856

  Decroix, J ^a   Ausma, J ^b   Cauwenbergh, G ^c   Borgers, M ^b,d   Wouters, L ^b  

^a Dermatology Clinic   (Belgium)

^b Barrier Therapeutics NV   (Belgium)

^c Barrier Therapeutics   (United States)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Phase IIa; Pramiconazole; Tinea corporis; Tinea cruris; Tinea pedis

Indexed keywords

ANTIFUNGAL AGENT; ITRACONAZOLE; PRAMICONAZOLE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; LETTER; PRIORITY JOURNAL; TINEA CORPORIS; TINEA CRURIS; TINEA PEDIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMIDAZOLES; MALE; TINEA PEDIS; TREATMENT OUTCOME; TRIAZOLES;

EID: 40949157529     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08420.x     Document Type: Letter

References (10)

1. Gupta AK, Ryder JE, Chow M et al. Dermatophytosis: the management of fungal infections. Skinmed 2005 4 : 305 10.
2. de Doncker P, Cauwenbergh G. Management of fungal skin infections with 15 days itraconazole treatment: a worldwide review. Br J Clin Pract 1990 71 (Suppl. 118 22.
3. Odds F, Ausma J, van Gerven F et al. In vitro and in vivo activities of the novel azole antifungal agent R126638. Antimicrob Agents Chemother 2004 48 : 388 91.
4. Vanden Bossche H, Ausma J, Bohets H et al. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother 2004 48 : 3272 8.
5. Piérard-Franchimont C, Ausma J, Wouters L et al. The activity of R126638, a new triazole antifungal, as assessed by corneofungimetry. Skin Pharmacol Physiol 2006 19 : 50 6.
6. Bell-Syer SE, Hart R, Crawford F et al. A systematic review of oral treatments for fungal infections of the skin of the feet. J Dermatol Treat 2001 12 : 69 74.
7. de Keyzer P, de Backer M, Massart DL et al. Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study. Br J Dermatol 1994 130 (Suppl. 43 22 5.
8. Svejgaard E, Avnstorp C, Wanscher B et al. Efficacy and safety of short-term itraconazole in tinea pedis: a double-blind, randomized, placebo-controlled trial. Dermatology 1998 197 : 368 72.
9. Gupta AK, de Doncker PD, Heremans A et al. Itraconazole for the treatment of tinea pedis: a dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks. J Am Acad Dermatol 1997 36 : 789 92.
10. Degreef H, Mariën K, de Veylder H et al. Itraconazole in the treatment of dermatophytes: a comparison of two daily dosages. Rev Infect Dis 1987 9 (Suppl. 1 S104 8.